Conversations with Dr Julie Suman, on Nasal Drug Delivery: Current trends, technical challenges and opportunities for therapeutic innovation
Aptar Pharma present data on the challenges and opportunities for Nasal drug delivery.
Nasal Drug Development, Trends and Challenges with Nasal Formulations
Nanopharm explores the current trends and technical challenges in nasal drug product development, focusing on formulation.
Raman Spectroscopy for Nasal Suspension Drugs
Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.
In Vitro System for Orally Inhaled Drug Release
Discover the development of an in vitro dissolution and release system from Nanopharm for OINDPs (orally inhaled drug products).
Raman Spectroscopy for Nasal Suspension Drugs
Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.
Faster, Cost-Effective Alternative to Generic Bioequivalence
Discover SmartTrack to advance the development of OINDPs. Streamline inhalation and nasal therapies with optimized particle size distribution.
Challenges in OINDPs Achieving Q3 Equivalence
Nanopharm review the bioequivalence challenges for OINDPs by achieving Q3 structural equivalence.
Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence
Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.
Characterizing Nasal Suspensions for Regulatory and Scientific Purposes
Explore Nanopharm’s in-depth research on particle size and its role in in vitro bioequivalence for nasal drug delivery. Discover how particle sizing impacts regulatory compliance and drug efficacy.
Cohesive-Adhesive Balances in DPIs
Explore Dry Powder Inhaler development through Atomic Force Microscopy. Uncover Cohesive-Adhesive balances in OINDP for effective inhaler formulations.
